| Market Capitalization (Millions $) |
411 |
| Shares
Outstanding (Millions) |
175 |
| Employees |
35 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-61 |
| Cash Flow (TTM) (Millions $) |
-125 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Inhibikase Therapeutics Inc is a biopharmaceutical company that focuses on the discovery and development of therapeutics to treat unmet medical needs in neurodegenerative diseases. The company's primary focus is on developing small molecule drugs that target kinases involved in neurodegenerative processes.
Inhibikase Therapeutics aims to develop treatments for diseases such as Parkinson's disease, Alzheimer's disease, and related disorders. The company leverages its expertise in kinases, which play a crucial role in regulating cellular processes, to develop novel therapies that can potentially slow or halt the progression of these debilitating diseases.
The company's drug candidates are designed to cross the blood-brain barrier, a protective barrier in the central nervous system that limits the entry of therapeutic agents. Inhibikase Therapeutics' innovative technology and approach have the potential to provide new treatment options for patients suffering from neurodegenerative conditions.
Inhibikase Therapeutics Inc is headquartered in Atlanta, Georgia, and collaborates with academic institutions, research organizations, and other biotech companies to advance its pipeline of drug candidates. The company's mission is to improve the lives of patients by developing innovative therapies that address the underlying causes of neurodegenerative diseases.
Company Address: 1000 Wilmington 19801 DE
Company Phone Number: 295-3800 Stock Exchange / Ticker: NASDAQ IKT
|
